OncoCyte Corp
NASDAQ:OCX

Watchlist Manager
OncoCyte Corp Logo
OncoCyte Corp
NASDAQ:OCX
Watchlist
Price: 2.71 USD 1.5% Market Closed
Market Cap: 45.6m USD
Have any thoughts about
OncoCyte Corp?
Write Note

OncoCyte Corp
Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

OncoCyte Corp
Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
OncoCyte Corp
NASDAQ:OCX
Long-Term Debt
$653k
CAGR 3-Years
30%
CAGR 5-Years
46%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Long-Term Debt
$58.5B
CAGR 3-Years
-8%
CAGR 5-Years
12%
CAGR 10-Years
15%
Gilead Sciences Inc
NASDAQ:GILD
Long-Term Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Long-Term Debt
$56.9B
CAGR 3-Years
20%
CAGR 5-Years
15%
CAGR 10-Years
6%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Long-Term Debt
$114m
CAGR 3-Years
-39%
CAGR 5-Years
-27%
CAGR 10-Years
-18%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Long-Term Debt
$2.7B
CAGR 3-Years
11%
CAGR 5-Years
31%
CAGR 10-Years
17%
No Stocks Found

OncoCyte Corp
Glance View

Market Cap
45.6m USD
Industry
Biotechnology

OncoCyte Corp. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. The company is headquartered in Irvine, California and currently employs 110 full-time employees. The company went IPO on 2015-12-30. The firm is focused on developing and commercializing proprietary tests, initially offered as laboratory-developed tests (LDTs), to serve unmet medical needs across the cancer care continuum. The Company’s products include DetermaRx, DetermaIO, and DetermaCNI. DetermaRx is a commercialized predictive molecular test for early-stage adenocarcinoma of the lung. This gene expression-based test provides information that a physician can use to identify early-stage, surgically resected patients with Stage I and IIA non-squamous non-small cell lung cancer (NSCLC). DetermaIO is developed to identify patients to respond to immunotherapy drugs. Its predictive biomarkers, including PD-L1 and Tumor Mutational Burden to predict, which patients responds to immunotherapy. DetermaCNI is a tumor-informed tests that are on market for treatment monitoring as well as blood-only targeted panels.

OCX Intrinsic Value
3.58 USD
Undervaluation 24%
Intrinsic Value
Price

See Also

What is OncoCyte Corp's Long-Term Debt?
Long-Term Debt
653k USD

Based on the financial report for Sep 30, 2024, OncoCyte Corp's Long-Term Debt amounts to 653k USD.

What is OncoCyte Corp's Long-Term Debt growth rate?
Long-Term Debt CAGR 5Y
46%

The average annual Long-Term Debt growth rates for OncoCyte Corp have been 30% over the past three years , 46% over the past five years .

Back to Top